GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Transgene Biotek Ltd (BOM:526139) » Definitions » Cyclically Adjusted Revenue per Share

Transgene Biotek (BOM:526139) Cyclically Adjusted Revenue per Share : ₹1.14 (As of Dec. 2024)


View and export this data going back to 2001. Start your Free Trial

What is Transgene Biotek Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Transgene Biotek's adjusted revenue per share for the three months ended in Dec. 2024 was ₹0.009. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹1.14 for the trailing ten years ended in Dec. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2025-05-17), Transgene Biotek's current stock price is ₹4.18. Transgene Biotek's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2024 was ₹1.14. Transgene Biotek's Cyclically Adjusted PS Ratio of today is 3.67.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Transgene Biotek was 8.15. The lowest was 2.94. And the median was 5.51.


Transgene Biotek Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Transgene Biotek's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Transgene Biotek Cyclically Adjusted Revenue per Share Chart

Transgene Biotek Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Transgene Biotek Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 1.27 1.21 1.14

Competitive Comparison of Transgene Biotek's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Transgene Biotek's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Transgene Biotek's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Transgene Biotek's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Transgene Biotek's Cyclically Adjusted PS Ratio falls into.


;
;

Transgene Biotek Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Transgene Biotek's adjusted Revenue per Share data for the three months ended in Dec. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=0.009/158.3229*158.3229
=0.009

Current CPI (Dec. 2024) = 158.3229.

Transgene Biotek Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
200903 0.000 56.615 0.000
201003 0.000 65.030 0.000
201103 0.000 70.768 0.000
201203 0.000 76.889 0.000
201206 0.827 79.567 1.646
201209 0.648 82.244 1.247
201212 0.717 83.774 1.355
201303 0.093 85.687 0.172
201403 0.000 91.425 0.000
201503 0.000 97.163 0.000
201603 0.000 102.518 0.000
201703 0.000 105.196 0.000
201803 0.000 109.786 0.000
201806 0.009 111.317 0.013
201809 0.000 115.142 0.000
201812 0.000 115.142 0.000
201903 0.000 118.202 0.000
201906 0.000 120.880 0.000
201909 0.000 123.175 0.000
201912 0.000 126.235 0.000
202003 0.000 124.705 0.000
202006 0.000 127.000 0.000
202009 0.000 130.118 0.000
202012 0.021 130.889 0.025
202103 0.002 131.771 0.002
202106 0.000 134.084 0.000
202109 0.000 135.847 0.000
202112 0.000 138.161 0.000
202203 0.011 138.822 0.013
202206 0.007 142.347 0.008
202209 0.000 144.661 0.000
202212 0.000 145.763 0.000
202303 0.000 146.865 0.000
202306 0.015 150.280 0.016
202309 0.007 151.492 0.007
202312 0.008 152.924 0.008
202403 0.007 153.035 0.007
202406 0.007 155.789 0.007
202409 0.008 157.882 0.008
202412 0.009 158.323 0.009

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Transgene Biotek  (BOM:526139) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Transgene Biotek's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=4.18/1.14
=3.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Transgene Biotek was 8.15. The lowest was 2.94. And the median was 5.51.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Transgene Biotek Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Transgene Biotek's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Transgene Biotek Business Description

Industry
Traded in Other Exchanges
N/A
Address
Anrich Industrial Area, Plot No. 69 and 70, IDA Bollaram, Sangareddy District, Medak, TG, IND, 502325
Transgene Biotek Ltd is an India-based research and development company. It is engaged in the research and development of molecules and technologies for the production of active pharmaceutical ingredients and other pharmaceutical products. The company is operating only in one segment of Bulk Drugs. Its product portfolio includes TrabiDHA, Tracolimus, and Orlistat. It generates revenue from the sale of goods and services.

Transgene Biotek Headlines

No Headlines